A new FDA-approved treatment for melanoma has hit the market with a high price, and clinicians are working with insurers to determine out-of-pocket costs for patients.
NCCN guidelines for cutaneous melanoma, issued in February, capture evolving data for both diagnosis and treatment, diverging incrementally from 2019 AAD guidelines.